KEI Comments: ERYTHRYx Therapeutics: Prospective Grant of an Exclusive Patent License on Methods of Modulating Erythropoiesis With Arginine Vasopressin Receptor 1B Molecules

UPDATE: On July 13, 2018, KEI received a response to our comments on the prospective license to be given to ERYTHRYx Therapeutics. The brief response simply stated that NIH had already assessed the company to meet their technical and financial… Continue Reading

NIH asked to extend comments on proposed license to Atara Biotherapeutics for patents on Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Human Cancer

On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading

KEI comments on prospective exclusive NIH license to streptococcus pneumonia patents, for the University of Liverpool

On July 2, 2018, Knowledge Ecology International (KEI) filed comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to the University of Liverpool, located in the U.K. The inventions described in the Federal… Continue Reading

WHO publishes Meeting Report of the Informal Advisory Group on the Availability and Affordability of Cancer Medicines

In May 2017, the 70th World Health Assembly passed a cancer resolution (WHA70.12, Cancer prevention and control in the context of an integrated approach). At the time KEI provided the following commentary on the cancer resolution: On Tuesday, May 30,… Continue Reading